TNFRSF9 and neoplasm: Our data show that rhCD137L-MSNs induce robust T cell costimulation, driving stronger tumor cytotoxicity than unconjugated urelumab or MSNs conjugated with urelumab (ure-MSNs) or utomilumab (uto-MSNs), the clinically most advanced anti-CD137 antibodies.